A workshop was sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases to focus on research gaps and opportunities on drug development for pancreatitis. This conference was held on July 25, 2018, and structured into 3 working groups (WG): acute pancreatitis (AP) WG, recurrent AP WG, and chronic pancreatitis WG. This article reports the outcome of the work accomplished by the AP WG to provide the natural history, epidemiology, and current management of AP; inform about the role of preclinical models in therapy selection; and discuss clinical trial designs with clinical and patient-reported outcomes to test new therapies.
From the *Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center;
†Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH;
‡Department of Medicine, University of California, Los Angeles;
§Pancreatic Research Group, UCLA/VA Greater Los Angeles Healthcare System, Los Angeles, CA;
∥Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD;
¶Department of Medicine, Dartmouth-Hitchcock Medical Center, Geisel School of Medicine, Darmouth University, Hanover, NH;
#MTA-SZTE Translational Gastroenterology Research Group, University of Szeged, Szeged;
**Institute for Translational Medicine and First Department of Medicine, Medical School, University of Pécs, Pécs, Hungary;
††Division of Digestive and Liver Diseases, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA;
‡‡Division of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Pittsburgh Medical Center;
§§Division of Gastroenterology and Hepatology, Veterans Affairs Pittsburgh Health System, Pittsburgh, PA;
∥∥Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL;
¶¶Division of Gastroenterology, Department of Medicine, University of John's Hopkins, Baltimore, MD;
##Stead Family Department of Pediatrics, University of Iowa, Stead Family Children's Hospital, Iowa City, IA; and
***Center for Pancreatic Care, Department of Gastroenterology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA.
Received for publication August 6, 2018; accepted August 28, 2018.
Address correspondence to: Maisam Abu-El-Haija, MD, Pancreas Care Center, Division of Gastroenterology, Hepatology and Nutrition, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave MLC 2010, Cincinnati, OH 45229 (e-mail: Maisam.Haija@cchmc.org).
The Hungarian National Research, Development and Innovation Office (K116634, KH125678). M.A.H, A.S.G., S.J.P., A.K.S., A.U., and B.U.W. acknowledge support from U01-108300 and others, which represent the Consortium for the Study of Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC). M.A.H. is supported by NIDDK (Grant Number 1K23DK118190-01). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
V.S. is a consultant to Abbvie, Akcea Therapeutics, and Ariel Precision Medicine; A.U. is a member of American Board of Pediatrics, Subboard of Pediatric Gastroenterology; G.P. received grant support from Abbvie and is a consultant to GlaxoSmithKline and Abbvie.
Supplemental digital contents are available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s Web site (www.pancreasjournal.com).